Loading...
Market
PTC518 Global Market Share in First Year Post-Launch?
2
Resolution / Starting Odds
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
Market analysis reports from industry analysts and financial reports
Story
PTC Therapeutics Secures $2.9B Deal with Novartis for Huntington's Drug, $1B Upfront
Dec 2, 2024, 01:09 PM
PTC Therapeutics Inc. has entered into a significant licensing agreement with Novartis AG, focusing on the development of PTC518, an experimental drug for Huntington's disease. The deal, which could be worth up to $2.9 billion, includes an upfront payment of $1 billion to PTC Therapeutics. Under the terms, Novartis will share U.S. profits and losses with PTC Therapeutics on a 40/60 basis, with PTC receiving 40%. This collaboration marks Novartis's renewed interest in Huntington's disease treatments. The agreement also involves global licensing and collaboration for the drug's development, with Novartis taking the lead in further development efforts.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 33%
United States only • 25%
United States and European Union • 25%
United States, European Union, and Japan • 25%
Other combinations or none • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%